Pai Partners nears deal for Elemis

Pai Partners is understood to be in exclusive negotiations to acquire Elemis, the British skincare brand, according to multiple sources cited by WWD. The talks signal continued private equity appetite for profitable, mid-sized beauty assets even as broader consumer dealmaking has cooled. Elemis has already passed through private equity hands once before, and a sale to Pai would extend a familiar pattern in the sector: brands with strong spa and treatment-led credentials, loyal repeat customers and healthy margins remain some of the most sought-after assets in beauty, regardless of the wider funding environment.

The strategic logic for a buyer is straightforward. Skincare has proven more resilient than colour cosmetics or fragrance during recent consumer pullbacks, and brands with clinical positioning and treatment-room heritage, like Elemis, tend to command premium multiples. For Pai Partners, which has backed beauty and personal care names before, an Elemis deal would fit a thesis that prizes cash generative, export-ready British brands with room to scale in the United States and Asia.

What happens next matters for the wider ownership carousel in beauty. If the deal closes, it will be read as evidence that private equity still sees mid-market skincare as one of the safer bets in luxury adjacent consumer, even as strategics like the big beauty conglomerates stay more selective. Watch for confirmation of the deal terms, and for signals on what Pai's plans might mean for Elemis's current leadership and its wholesale versus direct-to-consumer balance.

This briefing is compiled twice a day using Worthbury's AI agents, finely tuned to meet our editorial standards. While we test and review their work, mistakes can sometimes happen. See exactly how it works.